{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:50:00Z","timestamp":1792439400193,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014055","name":"U.S. Army Medical Research Acquisition Activity","doi-asserted-by":"publisher","award":["W81XWH-15-2-0077"],"award-info":[{"award-number":["W81XWH-15-2-0077"]}],"id":[{"id":"10.13039\/100014055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PT150, a novel competitive glucocorticoid receptor (GR) antagonist, has proven safe in animal models, healthy volunteers, and people with depression. Our study is the first to investigate PT150\u2019s safety with alcohol use. The primary objective of this study was to evaluate pharmacodynamic interactions between ethanol and PT150 in healthy subjects. This single-site, Phase I pilot trial consisted of community-recruited, healthy, alcohol-experienced participants aged 21\u201364\u00a0years. Of 32 participants screened, 11 were enrolled and randomized, one of which withdrew before intervention. PT150 (900\u00a0mg\/day) was administered orally to all participants for five days. All participants received two beverage challenges on Day 1 (before PT150 administration) and Day 5 (after PT150 administration). On challenge days, they received both alcohol (16% ethanol) and placebo (1% ethanol) beverages in random order. Primary outcomes included breath alcohol level, blood pressure, heart rate, adverse events, and electrocardiogram changes. There were no statistically significant differences in vital signs or estimated blood alcohol concentrations between PT150 non-exposed and exposed groups during the ethanol challenge. There were no clinically significant abnormal electrocardiograms or serious adverse events. These data show that administration of PT150 with concurrent alcohol use is safe and well-tolerated. This study supports a future pharmacokinetic interaction study between PT150 and alcohol.<\/jats:p><jats:p><jats:bold>Trial Registration<\/jats:bold> ClinicalTrials.gov Identifier: NCT03548714.<\/jats:p>","DOI":"10.1038\/s41598-021-88609-6","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:04:16Z","timestamp":1620641056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers"],"prefix":"10.1038","volume":"11","author":[{"given":"Claire","family":"Morice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewleen G.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Nolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Verrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"88609_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ijmm.2011.703","volume":"28","author":"M Donia","year":"2011","unstructured":"Donia, M. et al. Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. Int. J. Mol. Med. 28, 437\u2013442. https:\/\/doi.org\/10.3892\/ijmm.2011.703 (2011).","journal-title":"Int. J. Mol. Med."},{"key":"88609_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.biopsych.2007.08.012","volume":"63","author":"DL Evans","year":"2008","unstructured":"Evans, D. L. et al. Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus\/acquired immunodeficiency syndrome. Biol. Psychiatry 63, 899\u2013905. https:\/\/doi.org\/10.1016\/j.biopsych.2007.08.012 (2008).","journal-title":"Biol. Psychiatry"},{"key":"88609_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fphar.2020.00429","volume":"11","author":"F Diaz-Castro","year":"2020","unstructured":"Diaz-Castro, F., Monsalves-Alvarez, M., Rojo, L. E., Del Campo, A. & Troncoso, R. Mifepristone for treatment of metabolic syndrome: Beyond cushing\u2019s syndrome. Front. Pharmacol. 11, 429. https:\/\/doi.org\/10.3389\/fphar.2020.00429 (2020).","journal-title":"Front. Pharmacol."},{"key":"88609_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/oby.2010.51","volume":"18","author":"C Gross","year":"2010","unstructured":"Gross, C., Blasey, C. M., Roe, R. L. & Belanoff, J. K. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) 18, 2295\u20132300. https:\/\/doi.org\/10.1038\/oby.2010.51 (2010).","journal-title":"Obesity (Silver Spring)"},{"key":"88609_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005168.pub2","author":"P Gallagher","year":"2008","unstructured":"Gallagher, P. et al. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD005168.pub2 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"88609_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuroscience.2007.05.041","volume":"148","author":"K Kohda","year":"2007","unstructured":"Kohda, K. et al. Glucocorticoid receptor activation is involved in producing abnormal phenotypes of single-prolonged stress rats: A putative post-traumatic stress disorder model. Neuroscience 148, 22\u201333. https:\/\/doi.org\/10.1016\/j.neuroscience.2007.05.041 (2007).","journal-title":"Neuroscience"},{"key":"88609_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jpsychires.2005.08.002","volume":"40","author":"CS de Kloet","year":"2006","unstructured":"de Kloet, C. S. et al. Assessment of HPA-axis function in posttraumatic stress disorder: Pharmacological and non-pharmacological challenge tests, a review. J. Psychiatr. Res. 40, 550\u2013567. https:\/\/doi.org\/10.1016\/j.jpsychires.2005.08.002 (2006).","journal-title":"J. Psychiatr. Res."},{"key":"88609_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.04979.x","volume":"1179","author":"R Yehuda","year":"2009","unstructured":"Yehuda, R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann. N. Y. Acad. Sci. 1179, 56\u201369. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04979.x (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"88609_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006995.pub2","author":"B Garner","year":"2016","unstructured":"Garner, B., Phillips, L. J., Bendall, S. & Hetrick, S. E. Antiglucocorticoid and related treatments for psychosis. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD006995.pub2 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"88609_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mehy.2006.09.038","volume":"68","author":"V Dhikav","year":"2007","unstructured":"Dhikav, V. & Anand, K. S. Glucocorticoids may initiate Alzheimer\u2019s disease: A potential therapeutic role for mifepristone (RU-486). Med. Hypotheses 68, 1088\u20131092. https:\/\/doi.org\/10.1016\/j.mehy.2006.09.038 (2007).","journal-title":"Med. Hypotheses"},{"key":"88609_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12031-002-0033-3","volume":"19","author":"JK Belanoff","year":"2002","unstructured":"Belanoff, J. K., Jurik, J., Schatzberg, L. D., DeBattista, C. & Schatzberg, A. F. Slowing the progression of cognitive decline in Alzheimer\u2019s disease using mifepristone. J. Mol. Neurosci. 19, 201\u2013206. https:\/\/doi.org\/10.1007\/s12031-002-0033-3 (2002).","journal-title":"J. Mol. Neurosci."},{"key":"88609_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1196\/annals.1410.072","volume":"1148","author":"BW Peeters","year":"2008","unstructured":"Peeters, B. W., Ruigt, G. S., Craighead, M. & Kitchener, P. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann. N. Y. Acad. Sci. 1148, 536\u2013541. https:\/\/doi.org\/10.1196\/annals.1410.072 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"88609_CR13","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). 2018 National Survey on Drug Use and Health (NSDUH) Table 2.1B\u2014Tobacco Product and Alcohol Use in Lifetime, Past Year, and Past Month Among Persons Aged 12 or Older, by Age Group: Percentages, 2017 and 2018 (accessed 8 June 2020); https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHDetailedTabs2018R2\/NSDUHDetTabsSect2pe2018.htm#tab2-1b."},{"key":"88609_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant, B. F. et al. Epidemiology of DSM-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatr. 72, 757\u2013766. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0584 (2015).","journal-title":"JAMA Psychiatr."},{"key":"88609_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A. & Sellers, E. M. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br. J. Addict. 84, 1353\u20131357. https:\/\/doi.org\/10.1111\/j.1360-0443.1989.tb00737.x (1989).","journal-title":"Br. J. Addict."},{"key":"88609_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","volume":"83","author":"LC Sobell","year":"1988","unstructured":"Sobell, L. C., Sobell, M. B., Leo, G. I. & Cancilla, A. Reliability of a timeline method: Assessing normal drinkers\u2019 reports of recent drinking and a comparative evaluation across several populations. Br. J. Addict. 83, 393\u2013402. https:\/\/doi.org\/10.1111\/j.1360-0443.1988.tb00485.x (1988).","journal-title":"Br. J. Addict."},{"key":"88609_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","volume":"19","author":"MJ Bohn","year":"1995","unstructured":"Bohn, M. J., Krahn, D. D. & Staehler, B. A. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin. Exp. Res. 19, 600\u2013606 (1995).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"88609_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1530-0277.1993.tb00739.x","volume":"17","author":"CS Martin","year":"1993","unstructured":"Martin, C. S., Earleywine, M., Musty, R. E., Perrine, M. W. & Swift, R. M. Development and validation of the biphasic alcohol effects scale. Alcohol Clin. Exp. Res. 17, 140\u2013146. https:\/\/doi.org\/10.1111\/j.1530-0277.1993.tb00739.x (1993).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"88609_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/\/0022-3514.54.6.1063","volume":"54","author":"D Watson","year":"1988","unstructured":"Watson, D., Clark, L. A. & Tellegen, A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J. Pers. Soc. Psychol. 54, 1063\u20131070. https:\/\/doi.org\/10.1037\/\/0022-3514.54.6.1063 (1988).","journal-title":"J. Pers. Soc. Psychol."},{"key":"88609_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cpt1971122part1245","volume":"12","author":"WR Martin","year":"1971","unstructured":"Martin, W. R., Sloan, J. W., Sapira, J. D. & Jasinski, D. R. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245\u2013258. https:\/\/doi.org\/10.1002\/cpt1971122part1245 (1971).","journal-title":"Clin. Pharmacol. Ther."},{"key":"88609_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0376-8716(91)90054-3","volume":"28","author":"H de Wit","year":"1991","unstructured":"de Wit, H. & Griffiths, R. Methods of assessing the abuse liability of sedatives in humans. Drug Alcohol Depend. 28, 83\u2013111 (1991).","journal-title":"Drug Alcohol Depend."},{"key":"88609_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/j.1360-0443.1991.tb01749.x","volume":"86","author":"MW Fischman","year":"1991","unstructured":"Fischman, M. W. & Foltin, R. W. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br. J. Addict. 86, 1563\u20131570. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01749.x (1991).","journal-title":"Br. J. Addict."},{"key":"88609_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1530-0277.2000.tb02057.x","volume":"24","author":"L Holdstock","year":"2000","unstructured":"Holdstock, L., King, A. C. & Wit, H. Subjective and objective responses to ethanol in moderate\/heavy and light social drinkers. Alcohol Clin. Exp. Res. 24, 789\u2013794. https:\/\/doi.org\/10.1111\/j.1530-0277.2000.tb02057.x (2000).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"88609_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF01062525","volume":"20","author":"RD Purves","year":"1992","unstructured":"Purves, R. D. Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J. Pharmacokinet. Biopharm. 20, 211\u2013226. https:\/\/doi.org\/10.1007\/BF01062525 (1992).","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"88609_CR25","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.amjcard.2016.07.033","volume":"118","author":"Z Li","year":"2016","unstructured":"Li, Z. et al. Relation of heavy alcohol consumption to QTc interval prolongation. Am. J. Cardiol. 118, 1201\u20131206. https:\/\/doi.org\/10.1016\/j.amjcard.2016.07.033 (2016).","journal-title":"Am. J. Cardiol."},{"key":"88609_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.14423\/SMJ.0000000000000674","volume":"110","author":"T Chu","year":"2017","unstructured":"Chu, T., Azevedo, K., Ernst, A. A., Sarangarm, D. & Weiss, S. J. A comparison of QTc intervals in alcohol withdrawal patients versus acute coronary syndrome patients. S. Med. J. 110, 475\u2013479. https:\/\/doi.org\/10.14423\/SMJ.0000000000000674 (2017).","journal-title":"S. Med. J."},{"key":"88609_CR27","first-page":"223","volume":"136","author":"F Cuculi","year":"2006","unstructured":"Cuculi, F., Kobza, R., Ehmann, T. & Erne, P. ECG changes amongst patients with alcohol withdrawal seizures and delirium tremens. Swiss Med. Wkly. 136, 223\u2013227 (2006).","journal-title":"Swiss Med. Wkly."},{"key":"88609_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874192401812010001","volume":"12","author":"H Raheja","year":"2018","unstructured":"Raheja, H. et al. Electrocardiogram changes with acute alcohol intoxication: A systematic review. Open Cardiovasc. Med. J. 12, 1\u20136. https:\/\/doi.org\/10.2174\/1874192401812010001 (2018).","journal-title":"Open Cardiovasc. Med. J."},{"key":"88609_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12916-014-0182-6","volume":"12","author":"M Roerecke","year":"2014","unstructured":"Roerecke, M. & Rehm, J. Alcohol consumption, drinking patterns, and ischemic heart disease: A narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 12, 182. https:\/\/doi.org\/10.1186\/s12916-014-0182-6 (2014).","journal-title":"BMC Med."},{"key":"88609_CR30","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/hr.2015.77","volume":"38","author":"Y Takeshita","year":"2015","unstructured":"Takeshita, Y. et al. Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens. Res. 38, 741\u2013750. https:\/\/doi.org\/10.1038\/hr.2015.77 (2015).","journal-title":"Hypertens. Res."},{"key":"88609_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5603\/CJ.2013.0028","volume":"20","author":"B Darpo","year":"2013","unstructured":"Darpo, B., Bullingham, R., Combs, D. L., Ferber, G. & Hafez, K. Assessment of the cardiac safety and pharmacokinetics of a short course, twice daily dose of orally-administered mifepristone in healthy male subjects. Cardiol. J. 20, 152\u2013160. https:\/\/doi.org\/10.5603\/CJ.2013.0028 (2013).","journal-title":"Cardiol. J."},{"key":"88609_CR32","unstructured":"Center for Drug Evaluation and Research. Interdisciplinary Review Team for QT Studies Consultation: Thorough QT Study Review: New Drug Application for Mifepristone (2012)."},{"key":"88609_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jpsychires.2007.12.005","volume":"42","author":"P Gallagher","year":"2008","unstructured":"Gallagher, P., Watson, S., Elizabeth Dye, C., Young, A. H. & Nicol Ferrier, I. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia. J. Psychiatr. Res. 42, 1037\u20131041. https:\/\/doi.org\/10.1016\/j.jpsychires.2007.12.005 (2008).","journal-title":"J. Psychiatr. Res."},{"key":"#cr-split#-88609_CR34.1","unstructured":"EU Clinical Trials Register. Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects with Psychotic Major Depression (Major Depressive Episode, Severe, with Psychotic Features). (Accessed 29 December 2020)"},{"key":"#cr-split#-88609_CR34.2","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-002156-34\/results (2018)."},{"key":"88609_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/alcalc\/35.2.139","volume":"35","author":"C Fahlke","year":"2000","unstructured":"Fahlke, C. & Eriksson, C. J. Effect of adrenalectomy and exposure to corticosterone on alcohol intake in alcohol-preferring and alcohol-avoiding rat lines. Alcohol Alcohol 35, 139\u2013144. https:\/\/doi.org\/10.1093\/alcalc\/35.2.139 (2000).","journal-title":"Alcohol Alcohol"},{"key":"88609_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.brainresbull.2005.08.006","volume":"68","author":"MJ O'Callaghan","year":"2005","unstructured":"O\u2019Callaghan, M. J., Croft, A. P., Jacquot, C. & Little, H. J. The hypothalamopituitary-adrenal axis and alcohol preference. Brain Res. Bull. 68, 171\u2013178. https:\/\/doi.org\/10.1016\/j.brainresbull.2005.08.006 (2005).","journal-title":"Brain Res. Bull."},{"key":"88609_CR37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.psyneuen.2003.09.004","volume":"29","author":"HN Koenig","year":"2004","unstructured":"Koenig, H. N. & Olive, M. F. The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions. Psychoneuroendocrinology 29, 999\u20131003. https:\/\/doi.org\/10.1016\/j.psyneuen.2003.09.004 (2004).","journal-title":"Psychoneuroendocrinology"},{"key":"88609_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.brainresbull.2012.05.007","volume":"88","author":"A Rotter","year":"2012","unstructured":"Rotter, A. et al. Glucocorticoid receptor antagonism blocks ethanol-induced place preference learning in mice and attenuates dopamine D2 receptor adaptation in the frontal cortex. Brain Res. Bull. 88, 519\u2013524. https:\/\/doi.org\/10.1016\/j.brainresbull.2012.05.007 (2012).","journal-title":"Brain Res. Bull."},{"key":"88609_CR39","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1111\/j.1530-0277.2008.00799.x","volume":"32","author":"C Jacquot","year":"2008","unstructured":"Jacquot, C. et al. Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption. Alcohol Clin. Exp. Res. 32, 2107\u20132116. https:\/\/doi.org\/10.1111\/j.1530-0277.2008.00799.x (2008).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"88609_CR40","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1172\/JCI79828","volume":"125","author":"LF Vendruscolo","year":"2015","unstructured":"Vendruscolo, L. F. et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J. Clin. Investig. 125, 3193\u20133197. https:\/\/doi.org\/10.1172\/JCI79828 (2015).","journal-title":"J. Clin. Investig."},{"key":"88609_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.drugalcdep.2015.06.018","volume":"154","author":"AR Reynolds","year":"2015","unstructured":"Reynolds, A. R. et al. Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation. Drug Alcohol Depend. 154, 100\u2013104. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.06.018 (2015).","journal-title":"Drug Alcohol Depend."},{"key":"88609_CR42","doi-asserted-by":"publisher","first-page":"109680","DOI":"10.1016\/j.mehy.2020.109680","volume":"140","author":"ND Theise","year":"2020","unstructured":"Theise, N. D., Crawford, J. M., Nakanuma, Y. & Quaglia, A. Canal of Hering loss is an initiating step for primary biliary cholangitis (PBC): A hypothesis. Med. Hypotheses 140, 109680. https:\/\/doi.org\/10.1016\/j.mehy.2020.109680 (2020).","journal-title":"Med. Hypotheses"},{"key":"88609_CR43","doi-asserted-by":"publisher","first-page":"e15663","DOI":"10.1200\/JCO.2020.38.15_suppl.e15663","volume":"38","author":"P Tatman","year":"2020","unstructured":"Tatman, P. et al. Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity. J. Clin. Oncol. 38, e15663. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e15663 (2020).","journal-title":"J. Clin. Oncol."},{"key":"88609_CR44","doi-asserted-by":"publisher","first-page":"e16556","DOI":"10.1200\/jco.2015.33.15_suppl.e16556","volume":"33","author":"ND Theise","year":"2015","unstructured":"Theise, N. D. et al. Glucocorticoid receptor antagonist Org34517 as a chemosensitizing agent for ovarian cancer. J. Clin. Oncol. 33, e16556. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e16556 (2015).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88609-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:54:46Z","timestamp":1670054086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88609-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"29 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9876"}}